151 related articles for article (PubMed ID: 3520827)
1. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.
Rosenberg SA
Semin Oncol; 1986 Jun; 13(2):200-6. PubMed ID: 3520827
[No Abstract] [Full Text] [Related]
2. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA
Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
[No Abstract] [Full Text] [Related]
3. The current status and future applications of interleukin 2- and adoptive immunotherapy in cancer treatment.
Simpson C; Seipp CA; Rosenberg SA
Semin Oncol Nurs; 1988 May; 4(2):132-41. PubMed ID: 3287538
[No Abstract] [Full Text] [Related]
4. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Rosenberg SA; Lotze MT
Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
[No Abstract] [Full Text] [Related]
5. [Use of interleukin 2-activated lymphocytes (LAK cells) in adoptive immunotherapy of neoplasms].
Robak T
Pol Tyg Lek; 1988 Nov; 43(47):1491-5. PubMed ID: 3266975
[No Abstract] [Full Text] [Related]
6. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
[No Abstract] [Full Text] [Related]
7. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.
Rosenberg S
J Natl Cancer Inst; 1985 Oct; 75(4):595-603. PubMed ID: 3876465
[No Abstract] [Full Text] [Related]
8. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
9. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.
Lotze MT; Rosenberg SA
Immunobiology; 1986 Sep; 172(3-5):420-37. PubMed ID: 3100435
[TBL] [Abstract][Full Text] [Related]
10. [Adoptive immunotherapy using cytapheresis].
Takago H; Sasakawa H; Kanizawa Y; Nojiri H; Ueno Y
Rinsho Ketsueki; 1986 Jul; 27(7):1242-6. PubMed ID: 3491233
[No Abstract] [Full Text] [Related]
11. [In vitro induction of PHA-activated killer cells for adoptive immunotherapy of recurrent or residual malignant gliomas].
Shinoda J; Yamada H; Sakai N; Ando T; Miwa Y
Neurol Med Chir (Tokyo); 1987 Sep; 27(9):831-40. PubMed ID: 2451171
[No Abstract] [Full Text] [Related]
12. Immunotherapy of cancer: the end of the beginning?
Durant JR
N Engl J Med; 1987 Apr; 316(15):939-41. PubMed ID: 3493434
[No Abstract] [Full Text] [Related]
13. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
Kedar E; Zeira E; Lebendiker Z; Weiss DW; Katan R; Shouval D
Prog Clin Biol Res; 1987; 244():59-75. PubMed ID: 3498959
[No Abstract] [Full Text] [Related]
14. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
15. [The activation of natural killer cells. A new approach to adoptive immunotherapy of tumors].
Schwarz R
Fortschr Med; 1988 Oct; 106(29):579-80. PubMed ID: 3266178
[No Abstract] [Full Text] [Related]
16. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
Topalian SL; Rosenberg SA
Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.
Fagan EA; Eddleston AL
Gut; 1987 Feb; 28(2):113-6. PubMed ID: 3549471
[No Abstract] [Full Text] [Related]
19. Fluctuations of plasma beta 2-microglobulin, soluble interleukin 2 receptor and interferon-gamma concentrations after adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
Giannella G; Pelosi-Testa E; Carlini P; Habetswallner D; Montesoro E; Camagna A; Calzini V; Ruggeri EM; Arena MG; Masciulli R
Immunobiology; 1989 Feb; 178(4-5):305-15. PubMed ID: 2497064
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy of cancer with activated lymphocytes and interleukin-2.
Kradin RL; Kurnick JT
Pathol Immunopathol Res; 1986; 5(3-5):193-202. PubMed ID: 3299346
[No Abstract] [Full Text] [Related]
[Next] [New Search]
